Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06016738
Title OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)
Acronym OPERA-01
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Olema Pharmaceuticals, Inc.
Age Groups: adult | senior
Covered Countries USA | ITA | BEL | AUS

No variant requirements are available.